This can cause side effects such as those listed above
10.2337/db23-0553 40 KahlesF.MeyerC.MollmannJ.DieboldS.FindeisenH
Over half of the patients had tirzepatide dose de-escalation from 7.5 mg to 5 mg (28.6%) or from 5 mg to 2.5 mg (21.6%) (Fig
Therefore, six clinical targets were considered in the study, including different levels of glycemic control targets, weight management targets, and composite treatment endpoints: (1) HbA 1c 6.5%
Recent studies have revealed an autoregulatory mechanism whereby mitochondrial GSH (mtGSH) homeostasis is controlled through a feedback loop involving solute carrier family 25 member 39 (SLC25A39) transporter and mitochondrial protease AFG3 like matrix AAA peptidase subunit 2 (AFG3L2), coupling GSH levels to iron-sulfur cluster biogenesis 16,17
PubMed, Giannetti, Matthew P., et al